Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of romosozumab in postmenopausal women with low bone mineral density
2008-005991-28Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of romosozumab in postmenopausal osteoporosis and low bone mineral density (3 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at month 12. Started May 2009; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosislow bone mineral density
Beyond the preview
Go deeper on 2008-005991-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005991-28.